Caris Life Sciences Highlights Growing Urgency Of Closing Geographic Gap In Cancer Clinical Trial Access And Role Of RIT Clinical Trial Solution Plays In Bringing Biomarker-Driven Trials To Community Oncology Practices Nationwide

Comprehensive molecular profiling paired with biomarker-driven trial matching provides cancer patients with a complete pathway from diagnosis to treatment across more than 600 locations nationwide

IRVING, Texas, April 15, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today highlighted the growing urgency of closing the geographic gap in cancer clinical trial access and the role its Right-In-Time (RIT) clinical trial solution plays in bringing biomarker-driven trials to community oncology practices nationwide.

Research published in JCO Oncology Practice found that 70% of U.S. counties had no active cancer treatment trials, leaving nearly one in five Americans ages 55 and older without a local pathway to investigational therapies. Nearly 85% of U.S. cancer patients receive care at community-based practices, yet most clinical trials remain concentrated at large academic medical centers. A meta-analysis in the Journal of the National Cancer Institute found that 55% of cancer patients offered a trial agree to participate, suggesting the core barrier is access and infrastructure, not patient willingness.

The Caris RIT clinical trial solution addresses this challenge by deploying trials directly to community oncology sites. Drawing on decades of oncology clinical trial experience, the system is designed to move from molecular profiling to patient enrollment in approximately two weeks and in as few as five days. Patients remain under the care of their treating oncologist, preserving continuity of care and eliminating the burden of long-distance travel to academic centers.

The network of community and regional oncology sites now spans more than 600 locations, 2,200 investigators across the United States and Puerto Rico, with more than 71,000 patients identified for potential trial participation.